Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020221894 - ANTIVIRAL COMPOUNDS

Publication Number WO/2020/221894
Publication Date 05.11.2020
International Application No. PCT/EP2020/062122
International Filing Date 30.04.2020
IPC
A61P 31/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C07D 239/48 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46Two or more oxygen, sulfur or nitrogen atoms
48Two nitrogen atoms
A61K 31/496 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
CPC
A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C07D 239/48
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
239Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02not condensed with other rings
24having three or more double bonds between ring members or between ring members and non-ring members
28with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46Two or more oxygen, sulfur or nitrogen atoms
48Two nitrogen atoms
Applicants
  • UNIVERSITÄT WIEN [AT]/[AT]
  • UNIVERSITÄT INNSBRUCK [AT]/[AT]
  • KATHOLIEKE UNIVERSITEIT LEUVEN [BE]/[BE]
Inventors
  • MOESSLACHER, Julia
  • BATTISTI, Verena
  • LANGER, Thierry
  • URBAN, Ernst
  • PUERSTINGER, Gerhard
  • ABDELNABI, Rana
  • DELANG, Leen
  • JOCHMANS, Dirk
  • LEYSSEN, Pieter
  • MARCHAND, Arnaud
  • NEYTS, Johan
Agents
  • BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB
Priority Data
19172043.230.04.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIVIRAL COMPOUNDS
(FR) COMPOSÉS ANTIVIRAUX
Abstract
(EN)
The invention is provides novel antiviral compounds, as well as derivatives thereof. The compounds of the invention are preferably formulated as pharmaceuticals. The invention provides the compounds for use in the prevention and treatment of infectious diseases, in particular viral diseases. In some aspects the invention is based on the antiviral activity of the provided compounds against the Chikungunya virus, and hence, their application in the treatment or prevention of any physiological manifestation of such viral infection.
(FR)
L'invention concerne de nouveaux composés antiviraux, ainsi que des dérivés de ceux-ci. Les composés de l'invention sont de préférence formulés en tant que produits pharmaceutiques. L'invention concerne les composés destinés à être utilisés dans la prévention et le traitement de maladies infectieuses, en particulier de maladies virales. Dans certains aspects, l'invention concerne l'activité antivirale des composés de l'invention contre le virus Chikungunya, et par conséquent, leur application dans le traitement ou la prévention de toute manifestation physiologique d'une telle infection virale.
Latest bibliographic data on file with the International Bureau